Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
We describe a chemical proteomics approach to profile the interaction of small molecules with hundreds of endogenously expressed protein kinases and purine-binding proteins. This subproteome is captured by immobilized nonselective kinase inhibitors (kinobeads), and the bound proteins are quantified in parallel by mass spectrometry using isobaric tags for relative and absolute quantification (iTRAQ). By measuring the competition with the affinity matrix, we assess the binding of drugs to their targets in cell lysates and in cells. By mapping drug-induced changes in the phosphorylation state of the captured proteome, we also analyze signaling pathways downstream of target kinases. Quantitative profiling of the drugs imatinib (Gleevec), dasatinib (Sprycel) and bosutinib in K562 cells confirms known targets including ABL and SRC family kinases and identifies the receptor tyrosine kinase DDR1 and the oxidoreductase NQO2 as novel targets of imatinib. The data suggest that our approach is a valuable tool for drug discovery.
Bantscheff
Marcus
M
Cellzome AG, Meyerhofstrasse 1, D-69117 Heidelberg, Germany.
Eberhard
Dirk
D
Abraham
Yann
Y
Bastuck
Sonja
S
Boesche
Markus
M
Hobson
Scott
S
Mathieson
Toby
T
Perrin
Jessica
J
Raida
Manfred
M
Rau
Christina
C
Reader
Valérie
V
Sweetman
Gavain
G
Bauer
Andreas
A
Bouwmeester
Tewis
T
Hopf
Carsten
C
Kruse
Ulrich
U
Neubauer
Gitte
G
Ramsden
Nigel
N
Rick
Jens
J
Kuster
Bernhard
B
Drewes
Gerard
G
D001549:Benzamides; D002457:Cell Extracts; D002846:Chromatography, Affinity; D000070819:Discoidin Domain Receptor 1; D004800:Enzymes, Immobilized / Q000037:antagonists & inhibitors; D006367:HeLa Cells; D006801:Humans; D000068877:Imatinib Mesylate; D020128:Inhibitory Concentration 50; D020014:K562 Cells; D004364:Pharmaceutical Preparations; D010766:Phosphorylation / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D040901:Proteomics / Q000379:methods*; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000494:pharmacology; D011808:Quinone Reductases / Q000037:antagonists & inhibitors; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects
D001549:Benzamides; D002457:Cell Extracts; D004800:Enzymes, Immobilized; D004364:Pharmaceutical Preparations; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C419642:NRH - quinone oxidoreductase2; D011808:Quinone Reductases; C092030:DDR1 protein, human; D000070819:Discoidin Domain Receptor 1; D020794:Receptor Protein-Tyrosine Kinases; D016315:Proto-Oncogene Proteins c-abl